Foroohar and Oppenheimer Maintain Buy Rating for Benitec Biopharma with Price Target

Summary

Foroohar and Oppenheimer have maintained a Buy rating on Benitec Biopharma, with price targets of $24.75 and $29.00 respectively, indicating an 85.25% upside from current levels.Tip Ranks

Impact Analysis

So basically, Benitec Biopharma is getting a lot of love from analysts right now. Both Foroohar and Oppenheimer have reiterated their Buy ratings, with price targets suggesting substantial upside—85.25% from current levels according to consensus.Tip Ranks The interesting part isn’t just the ratings themselves, but the timing. With healthcare stocks often being volatile, this could signal confidence in Benitec’s pipeline or strategic moves that aren’t fully appreciated by the market yet. Everyone’s focused on the upside, but the real story might be about what Benitec is doing right now to justify these targets. Are they on the brink of a breakthrough, or is there a strategic partnership in the works? I’d read this as a potential opportunity to get in before the market catches up. Watch for any news on clinical trials or partnerships that could further validate these bullish targets.